Point-of-Care Cepheid Xpert HIV-1 Viral Load Test in Rural African Communities Is Feasible and Reliable
- 1 December 2016
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 54 (12), 3050-3055
- https://doi.org/10.1128/jcm.01594-16
Abstract
Routine monitoring of HIV-1 RNA or viral load (VL) in patients on antiretroviral therapy (ART) is important, but there are multiple impediments to VL testing in resource-constrained settings. An accurate point-of-care (POC) HIV-1 VL test could alleviate many of these challenges. We compared the performance of the Cepheid Xpert HIV-1 VL assay against the laboratory-based Abbott m 2000sp/ m 2000rt assay (Abbott assay). ART-naive individuals participating in the Botswana Combination Prevention Project in 20 communities provided EDTA-blood specimens during household surveys. Both the POC Xpert HIV-1 VL and Abbott assays were performed on specimens sampled from 277 individuals. We found a high correlation between the Xpert HIV-1 VL and Abbott assay results ( r 2 = 0.92; P < 0.001). The overall mean difference in the HIV-1 RNA values obtained by Xpert HIV-1 VL assay and Abbott assay was 0.34 log 10 copies/ml (95% confidence interval [CI], 0.26 to 0.40 log 10 copies/ml) ( P < 0.001). Using a clinically relevant level of 1,000 copies/ml as a threshold, agreement was 90.6% (95% CI, 87.9 to 93.1%), with a sensitivity of 98.6% (95% CI, 97.2 to 100%). The two methods agreed on their detectability of HIV-1 RNA (>40 copies/ml) at 97.1% (95% CI, 95.5 to 98.7%), with a sensitivity of 99.6% (95% CI, 97.2 to 100%). The POC Cepheid Xpert HIV-1 VL assay showed high agreement and accuracy with a laboratory-based method of HIV-1 RNA testing. The POC Xpert HIV-1 VL assay tended to overestimate HIV-1 VL, although the difference was below a clinically relevant threshold of 0.5 log 10 copies/ml. The POC Cepheid Xpert HIV-1 VL assay is a promising tool for monitoring patients on ART in southern Africa.Keywords
Funding Information
- U.S. President's Emergency Plan for AIDS Relief (U01 GH000447)
- Wellcome Trust DELTAS Initiatives/Sub-Saharan Africa Network for TB/HIV Research Excellence (107752/Z/15/Z)
This publication has 26 references indexed in Scilit:
- Comparison of the Cepheid GeneXpert and Abbott M2000 HIV-1 real time molecular assays for monitoring HIV-1 viral load and detecting HIV-1 infectionJournal of Virological Methods, 2016
- Viral-load point-of-care technologies to achieve an AIDS-free generationFuture Microbiology, 2016
- Scale-up of HIV Viral Load Monitoring — Seven Sub-Saharan African CountriesMorbidity and Mortality Weekly Report (MMWR), 2015
- Printed Flexible Plastic Microchip for Viral Load Measurement through Quantitative Detection of Viruses in Plasma and SalivaScientific Reports, 2015
- Laboratory Evaluation of the Liat HIV Quant (IQuum) Whole-Blood and Plasma HIV-1 Viral Load Assays for Point-of-Care Testing in South AfricaJournal of Clinical Microbiology, 2015
- Systematic Review of the Performance of HIV Viral Load Technologies on Plasma SamplesPLOS ONE, 2014
- Challenges in implementing HIV laboratory monitoring in resource-constrained settings: how to do more with lessFuture Microbiology, 2011
- Simple Amplification‐Based Assay: A Nucleic Acid–Based Point‐of‐Care Platform for HIV‐1 TestingThe Journal of Infectious Diseases, 2010
- HIV viral load markers in clinical practiceNature Medicine, 1996